课题基金 / 基金详情

ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL

ALTERNATIVE DOSING OF EXEMESTANE IN POSTMENOPAUSAL WOMEN WITH STAGE 0-II ER-POSITIVE BREAST CANCER: A RANDOMIZED PRESURGICAL TRIAL
患有 0-II 期 ER 阳性乳腺癌的绝经后女性依西美坦的替代剂量：一项随机术前试验
批准号：
9931092
负责人：
POWEL BROWN
金额：
$3.03万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
项目状态：
已结题
起止时间：
2015-08-01 至 2020-07-31
来源：
https://reporter.nih.gov/project-details/9931092
关键词：
AddressBenignClinical TrialsDoseDouble-Blind MethodEstradiolEstrogen receptor positiveExemestaneHistologicIntraepithelial NeoplasiaOperative Surgical ProceduresPatientsPharmaceutical PreparationsPharmacogeneticsPhasePostmenopauseProteomicsRandomizedRegimenSafetySerumStructureTimeTissue SampleTissuesToxic effectWomancirculating biomarkersmalignant breast neoplasmneoplastic celltissue biomarkers

项目摘要

项目成果

POWEL BROWN的其他基金

相似基金

相关文献

中文摘要
翻译
该临床试验是一项手术前IIb期、随机、双盲、多中心研究，研究对象是组织学证实为er阳性乳腺癌（0-II期）的绝经后患者，比较依西美坦标准剂量方案与两种频率较低的替代剂量方案。该临床试验将探讨依西美坦交替给药是否会导致血清雌二醇的非劣等降低。
英文摘要
This clinical trial is a pre-surgical Phase IIb, randomized, double-blind, multi-centric study for postmenopausal patients with histologically confirmed ER-positive breast cancer (Stage 0-II) comparing the Exemestane standard dose regimen versus two alternative, less frequent dose regimens. The clinical trial will address alternate dosing of Exemestane results in non-inferior reductions in serum estradiol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
海外基金